background: Ovarian stimulation regimens for in vitro fertilization seem to have a deleterious effect on oocyte quality and embryo aneuploidy in a dose-dependent manner. This study aims to test the influence of gonadotrophin doses on embryo aneuploidy rates.
Introduction
In recent years, there has been increasing controversy over the genetic risks of Assisted Reproductive Technology (ART), particularly related to in vitro fertilization (IVF) treatments. Preliminary studies suggest that aneuploidy rates in embryos may be altered by ovarian stimulation protocols employed in IVF, as well as patient estradiol (E 2 ) levels and the number of retrieved oocytes (Munne et al., 1997 (Munne et al., , 2006 Soares et al., 2003; Katz-Jaffe et al., 2005) .
Previous reports from preimplantation genetic screening (PGS) programmes have shown contradictory results. For example, Gianaroli et al. (2000) reported a similar incidence of chromosomally abnormal embryos, independent of the number of retrieved oocytes, in both patients with advanced maternal age and recurrent implantation failure. However, polar body testing has shown a higher incidence of chromosome abnormalities in two groups of patients with high oocyte yield: women less than 35 years old and between 35 and 40 years old (Haaf et al., 2009) .
Several authors have hypothesized that mild stimulation protocols or natural cycles would reduce aneuploidy (Nargund et al., 2001; Pelinck et al., 2005) . Baart et al. (2007) conducted a prospective randomized study comparing PGS results in conventional ovarian stimulation versus mild stimulation regimens. These authors considered a group of young IVF patients without additional indications for PGS, and found a lower frequency of chromosomal abnormalities with the mild stimulation protocol. More recently, to produce more 'friendly' IVF protocols and help to avoid the side effects of ovulation induction protocols, unstimulated IVF cycles were performed in conjunction with PGS. Aneuploidies were detected in 4 out of 11 embryos, demonstrating that aneuploidies were present in human embryos even in the absence of ovarian stimulation (Verpoest et al., 2008) . In a previous report comparing embryo morphology in stimulated versus unstimulated cycles, no differences were found in embryo quality (Ziebe et al., 2004) .
In a previous study (Soares et al., 2003) , we described high aneuploidy rates (56.5%) in Day-3 embryos from young high responder donors with a mean number of 25.9 retrieved oocytes. If we compare this aneuploidy rate to 37.3% chromosomally abnormal embryos in young fertile normal responder patients undergoing PGS due to sex-linked diseases (where lower E 2 peak and significantly lower number of oocytes were retrieved than in the donors group), the increase in chromosomally abnormal embryos could be attributed to the high ovarian response to gonadotrophins. Munne et al. (2006) confirmed that a large oocyte cohort from normal oocyte donors could result in up to 50% chromosomally abnormal embryos. More recently, Keskintepe et al. (2007) in a comparison study using FISH and comparative genomic hybridization (CGH), noted even higher aneuploidy rates by CGH in young donors.
Because of our previous results and other authors' publications, we conducted this study to determine the impact of different gonadotrophin doses on the percentage of aneuploidy and the total number of chromosomally normal blastocysts as the primary outcome measures reflecting the reproductive efficiency of the subsequent treatment cycles.
Materials and Methods

Design
This is a crossover study in which PGS was performed on the embryos resulting from two stimulation regimens: in the first cycle (standard cycle), donors received a standard stimulation dose and in the second cycle (reduced dose cycle), the same donors received a 30% decreased dose from the previous dose, with an interval of at least 3 months. Of the 22 donors with two completed cycles (standard and reduced dose cycles), for 7 patients the interval between the two donations was 3 months, for 6 patients the interval was 6 months and for the remaining patients the interval between donations was more than 1 year.
Oocyte donors
The study included a total of 32 high responder donors from our oocyte donation programme. Inclusion criteria were donors with more than 20 oocytes or serum E 2 levels .3000 pg/ml on the day of hCG in a previous cycle with standard stimulation, without developing ovarian hyperstimulation syndrome. This study was approved by the Institutional Review Board on the use of human subjects in research at the Instituto Universitario-IVI, Valencia, Spain. All donors were included in our oocyte donation programme after being thoroughly informed and having fulfilled our inclusion criteria (Soares et al., 2005) . Subjects were between 18 and 35 years old; we had access to their complete medical history, which included current or past exposure to radiation or hazardous chemical substances, intravenous drug use and reproductive history. All subjects were found to be normal in a physical and gynaecological examination, had no family history of hereditary or chromosomal diseases, had a normal karyotype and tested negative for Fragile X Syndrome. The donors admitted to the study had normal menstrual cycles of 26 -34 days duration, normal weight (BMI of 18 -28 Kg/m 2 ), no endocrine treatment (including gonadotrophins and oral contraception) in the 3 months preceding the study, and normal uterus and ovaries at transvaginal ultrasound (Garrido et al., 2002) . Donors with a diagnosis of PCOS according to Rotterdam criteria were excluded (Rotterdam Consensus Workshop Group, 2004) .
GnRH agonist protocols were used for controlled ovarian stimulation (COS) and patients started administration of 0.5 mg of leuprolide acetate (Procrin w ; Abbott, Madrid, Spain) in the mid-luteal phase of the previous cycle, until a negative vaginal ultrasound defined ovarian quiescence. The dose of GnRH agonist was then decreased to 0.25 mg until the day of hCG administration (Melo et al., 2006) .
Oocyte donors underwent two consecutive cycles with the following two different doses of gonadotrophins to perform COS: † Standard dose cycle: the fixed starting dose of gonadotrophins was 225 IU/day of recombinant FSH (r-FSH) (Gonal-F w ; Merck-Serono, Geneve, Switzerland or Puregon; MSD, NJ, USA) for the first 5 days. Then, a serum E 2 determination was performed for individual adjustments as follows: if E 2 was ,400 pg/ml, the dose was increased to 300 IU/day; if E 2 was between 400 and 600 pg/ml, then the dose was maintained at 225 IU/day; if E 2 was .600 pg/ml, the dose was lowered to 150 IU/day. † Reduced dose cycle: at least 3 months later all of the donors were enrolled in a new COS cycle with 150 IU/day of r-FSH (Gonal-F w ; Merck-Serono, Geneve, Switzerland; or Puregon, MSD, NJ, USA). In this protocol the dose of r-FSH was never increased in spite of the response, but the r-FSH dose was decreased if E 2 was .600 pg/ml after 5 days of stimulation.
Initially, 32 donors underwent the standard dose cycle, but in the reduced dose cycle, 10 were cancelled due to an inadequate response for the purpose of oocyte donation in our clinical programme (defined as less than five follicles greater than 18 mm on day of hCG stimulation). Therefore, 22 donors successfully underwent both stimulation protocols (Fig. 1) .
When at least five follicles reached 18 mm in diameter, recombinant hCG (Ovitrelle w , 250 mg, Merck-Serono, Geneva, Switzerland) was administered and oocyte retrieval by transvaginal ultrasound-guided puncture of follicles was scheduled 36 h later. Serum E 2 and P levels were measured on the morning of hCG administration.
Oocyte recipients
Oocyte recipients (n ¼ 60) were admitted in our oocyte donation programme due to low response to stimulation (11%), endometriosis (11%), premature ovarian failure (17%), advanced maternal age (58%) or genetic or chromosomal disorders of maternal origin (3%).
In all cases, intracytoplasmic sperm injection (ICSI) was performed with motile and normal morphology ejaculated sperm. Cases with uterine pathology (submucous or larger than 2 cm intramural fibroids, polyps, adhesions, adenomyosis or müllerian defects), recurrent miscarriage, age .49 years old or severe male infertility (,5 million of fresh spermatozoa/ml, ,5% normal forms and/or non-obstructive azoospermia) were not included in the present study.
Embryo quality in high responder donors
The protocol for hormonal replacement therapy (HRT) was described previously (Remohí et al., 1995) . A baseline transvaginal scan was carried out prior to down-regulation to ensure that the uterus and ovaries were normal. For all recipients who were still cycling, down-regulation was performed using an IM dose of 3.75 mg of Triptorelin (Decapeptyl w ; Ipsen Pharma; Barcelona, Spain) in the mid-luteal phase of the previous cycle. HRT was initiated on Day 1 -3 of the following cycle, and doses of estradiol valerate (Progynova w ; Schering Spain, Madrid, Spain) were increased as follows: 2 mg/day for the first 8 days of treatment, 4 mg/ day for the following 3 days and a minimum of 6 mg/day until the pregnancy test. On Day 15, an ultrasound was performed to evaluate endometrial growth. On the day after the donation, 800 mg/day of micronized intravaginal progesterone (Progeffik w ; Effik Laboratories, Madrid, Spain) was administered. After signing written consent, PGS for chromosomes 13, 15, 16, 17, 18, 21, 22 , X and Y was performed in the resulting embryos and embryo transfer was carried out on Day 5 of development.
Embryo biopsy and culture conditions
After oocyte retrieval, IVF and embryo culture were performed as described previously (Mercader et al., 2006) . Fertilization was assessed 17 -20 h following microinjection and embryo cleavage was recorded every 24 h. Embryos were grown in IVF medium: CCM medium (1:1) (Vitrolife AB, Kungsbacka, Sweden) on Day 2 and subsequently cultured in CCM medium with a monolayer of endometrial epithelial cells from Day 2 until Day 5, when embryo transfer was performed.
Embryo biopsy was performed on Day 3. Embryos were placed on a droplet containing Ca 2+ and Mg 2+ free medium (G-PGD, Vitrolife) and the zona pellucida was perforated using laser technology (OCTAX, Herbron, Germany). Only embryos with ≥5 nucleated blastomeres and ≤25% of fragmentation degree were biopsied and one or two blastomeres were aspirated depending on the cell number on Day 3 (one blastomere was biopsied in embryos with 5 -7 blastomeres and two blastomeres in embryos with ≥8 blastomeres). Individual blastomeres were fixed onto glass slides under an inverted microscope, using a slightly modified Tarkowski's protocol (Tarkowski et al., 1966) .
FISH protocol for PGS Chromosomes 13, 15, 16, 17, 18, 21, 22 , X and Y were analysed by FISH in two consecutive rounds. In the first hybridization round, chromosomes 13, 16, 18, 21 and 22 were analysed using MultiVysion PB panel probe (Vysis Inc., Downers Grove, IL, USA). Co-denaturation of DNA from the nuclei and probes was performed in a thermoplate for 4 min at 73 + 18C, followed by 3 h of hybridization at 378C. In a second hybridization round, chromosomes 15, 17, X and Y were analysed with Multi Vysion 4 Custom Color panel probe (Vysis Inc., Downers Grove) after co-denaturation and 1 h of hybridization at 428C. Nuclei with nonconclusive signals (overlapping, fibre or split signals) or with absence of signals for any of the tested chromosomes were re-analysed using subtelomeric probes. An embryo was defined as normal when all blastomeres analysed from this embryo (one or two) showed two clear and separated dots for each of the tested autosomes and one or two dots for sex chromosomes. An embryo was considered as abnormal when all blastomeres analysed from this embryo (one or two) showed a different number of signals. Embryos considered as mosaic were those with two cells showing discordant signal numbers for one or more chromosomes. Slides were analysed using an Olympus AX-70 epifluorescence microscope (Olympus Optical Co., Hamburg, Germany) equipped with a triplebandpass filter for DAPI/Texas Red/FITC and single-bandpass filters for FITC, Texas Red, Gold, Aqua-Blue and Blue.
Outcome measures
Primary outcome measures were ovarian response, assessed by the number of retrieved oocytes, the percentage of aneuploid embryos and the total number of chromosomally normal blastocysts, defined in this paper as embryos diagnosed as normal on Day 3 after biopsy and that subsequently develop into blastocysts.
Secondary outcome measures were the fertilization rate, total gonadotrophin doses, estradiol levels on the day of hCG and pregnancy outcome in terms of implantation, pregnancy, miscarriage and live birth rates. Implantation rate was obtained by dividing the number of gestational sacs seen in ultrasound by the number of replaced embryos. Clinical pregnancy was considered when the embryonic sac(s) was/were seen by vaginal ultrasound from the fifth week of pregnancy. Early miscarriage was defined as a loss before 12 weeks (according to the definition of the ESHRE special interest group of early pregnancy).
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows, version 15.0 (SPSS, Chicago, IL, USA) and MedCalc Software (Ghent, Mariakerke, Belgium). The means of the continuous variables analysed followed a normal distribution and were analysed with Student's t-test. Fisher's test was used to assess the significance of categorical parameters. A power analysis was performed for all variables statistically significant (a , 0.05). Only those variables with a power higher than 80% were considered significant.
Results
A total of 32 donors started the standard dose cycle, but only 22 donors completed both cycles. For the remaining 10 donors, the reduced dose cycle was cancelled due to low ovarian response. Of the 22 donors who completed both treatments, in the standard dose cycle, none of the donors lowered the dose depending on the E 2 level in the first five stimulation days, but eight donors reduced the dose the day before HCG administration, whereas in the reduced dose cycle, initial doses did not change along the treatment. For 3 of the 10 uncompleted donors, doses were increased after 5 days of stimulation. Table I shows the results of ovarian stimulation and oocyte donation in the 10 donors with only the standard dose cycle and the corresponding 10 recipients. In the 22 completed donors, comparisons between standard dose and reduced dose cycles were performed (Table II) . The significant decrease in daily gonadotrophin administration (P ¼ 0.0086) resulted in a significant decrease in E 2 levels measured on the day of hCG administration (P ¼ 0.0019), and a significant decrease in the number of oocytes retrieved (P , 0.0001). A total of 50 women received donated oocytes from these 22 donors. Comparisons between the standard and reduced dose cycles showed a significant increase in rates of fertilization (P ¼ 0.0312), blastocyst development (0.0441) and chromosomally normal blastocysts (P ¼ 0.0236), with reduced doses. No significant differences were found in the percentage of chromosomally abnormal embryos with both treatments. In the recipients, the pregnancy outcome was similar with in two stimulation protocols, with a similar number of live births after the two treatments.
In the 22 donors with two completed cycles (standard and reduced dose cycles), the median of the difference between the number of MII oocytes retrieved with standard and reduced doses was 8. Donors were categorized in two different groups according to the difference in MII oocyte number between the two stimulation cycles: Group 1, 9 donors with differences below the median (similar numbers of MII oocytes recovered in standard and reduced dose cycles) and Group 2, 13 donors with differences above the median (half number of MII oocytes recovered in the reduced dose cycle compared with the standard dose cycle). Basal hormone levels, previous reproductive history and demographics were similar for each donor subgroup.
In Group 1 (Table III) , reduced doses significantly improved fertilization rates (P ¼ 0.0269), with an increased percentage of chromosomally normal blastocysts per MII oocyte, resulting in a higher mean number of normal blastocysts and a 2-fold increase in live births per donor. The percentages of chromosome abnormalities were 65.5% with the standard protocol and 50.9% with reduced doses, and the percentages of mosaic embryos when two cells per embryo were analysed were 43.5 and 27.3%, respectively (the differences were not statistically significant). In this subgroup, when we analysed abnormalities for each chromosome individually, we observed a significant increase in aneuploidies for chromosome 13 (P ¼ 0.0105) and a trend towards higher aneuploidy rates with the standard protocol for most of the tested chromosomes (data not shown).
In Group 2 (Table IV) , the decrease of gonadotrophin doses produced a significant decrease in both E 2 levels (P ¼ 0.0019) and the number of MII oocytes recovered (P , 0.0001). However, no improvement was observed for any of the analysed parameters, and the number of live births was half of that achieved with standard doses. Chromosome abnormalities were similarly distributed in both stimulation regimens, without differences in either the total percentage of abnormalities (47.3 versus 49.4%) or abnormalities for each individual chromosome.
After categorization in these two groups, mean daily gonadotrophins doses, stimulation days and total gonadotrophin doses did No. of live births 3 6 -*Informative embryos were defined as embryos with a conclusive result after FISH analysis. **Discordant results between blastomeres when two cells were analysed.
Comparisons between standard dose and reduced dose were performed in recipients with two completed cycles using Student's t-test and Fisher's exact test.
not show statistical differences either for the standard protocol or for the reduced dose protocol when comparing between Groups 1 and 2.
Discussion
In this study we have described a significant increase in fertilization, blastocyst and chromosomally normal blastocyst development rates in high responder donors after receiving a reduced dose of gonadotrophins in a second cycle. The improvement in these variables compensated for the decrease in oocyte number following the reduced dose protocol. Therefore, the efficiency of oocyte donation cycles was similar with the two stimulation therapies in terms of the reproductive outcome of the recipients and the total number of live births. A number of other studies support the findings we report here, namely that of high embryo aneuploidy rates ( 50%) in high responder donors with high E 2 levels during ovarian stimulation, and an overall improvement of blastocyst development rates with the decreased gonadotrophin doses. In women undergoing IVF, there appears to be no increase in the incidence of chromosome abnormalities in aborted fetuses when compared with natural conceptions (Plachot, 1989; Ma et al., 2006; Martínez et al., 2010) . However, in IVF cycles with a high response or even hyperstimulation syndrome, an increased risk of miscarriage and fetal aneuploidy has been reported (Nasseri et al., 1999; Raziel et al., 2002; O'Brien et al., 2009) . Several studies in oocyte donation programmes have described high incidences of chromosome abnormalities on Day-3 embryos from oocyte donors with high oocyte yield recovery (Soares et al., 2003; Nelson et al., 2005; Munne et al., 2006) . Additionally, our group showed that culture of mouse embryos with increasing E 2 levels impaired blastocyst formation and embryo adhesion (Valbuena et al., 2001) . Taken together, these studies suggest that stimulation protocols and the type of response would have a direct effect on embryo quality, the number of blastocyst and aneuploidy.
In our study, the second treatment was started at least after 3 months, since it has been stated that this is the time needed for renewing the follicular pool (Gougeon hyphotesis). Moreover, our group performed a study to evaluate the effect of repeated COS in donors and the oocyte retrieval rate was maintained through consecutive cycles. No adverse effects of repeated stimulations were found in the quantity or the quality of the retrieved oocytes (Caligara et al., 2001) . Therefore, the differences observed in embryo number and quality cannot be attributed to repeated stimulations and/or the interval between cycles in the same donors.
In recent years, many authors have proposed more physiological stimulation protocols to avoid the adverse effects of ovarian stimulation. Mild stimulation protocols aim to induce only a subtle interference in the physiological process of follicle domination (Fauser et al., 1999; Hohmann et al., 2003; Heijnen et al., 2007; Polinder et al., 2008; Verberg et al., 2009) , assuming that these regimens will select the healthiest, chromosomally normal oocytes with the additional benefits of lower costs and less patient discomfort; but still, mild stimulation would not guarantee a complete selection against chromosomally abnormal embryos, since a moderate incidence of aneuploidy has still been reported in IVF embryos from mild stimulation protocols (Baart et al., 2007) .
Ovarian stimulation in IVF/ICSI treatments induces the development and growth of multiple follicles, resulting in high numbers of oocytes for retrieval. In natural cycles, around the mid-follicular phase, the most mature follicle gains dominance over other cohort follicles. This dominant follicle continues its growth despite decremented FSH concentrations, whereas the remaining follicles from the recruited cohort enter atresia due to insufficient stimulation by FSH (Fauser et al., 1993 ). An FSH 'window' may exist, whereby an upper FSH limit does not increase the follicle recruitment when such a limit is exceeded, while a lower 'threshold' prohibits the follicle development if it is not reached. An interesting observation of our study is that responses to the same reduced doses of gonadotrophins vary, as seen when dividing the patients into two response groups. In Group 1, both treatments resulted in a similar recovery of MII oocytes, suggesting that the standard dose had exceeded the FSH 'ceiling'. This excessive dose led to a decreased percentage of chromosomally normal blastocysts and a trend towards decreased implantation rates with the standard stimulation protocol. In Group 2, however, the reduced dose resulted in the recovery of 50% fewer MII oocytes, suggesting that both regimens appear between the limits of the FSH 'window'. Subsequently, similar rates of development of chromosomally normal blastocyst and implantation were obtained in Group 2. Yet a third pattern also emerged in 'uncompleted donors', in which a drastic reduction in the follicular development forced cancellation due to a very low response. These patients are likely to have a very narrow FSH window. Munne et al. (2006) also reported high variability in the incidence of chromosome abnormalities in embryos from young oocyte donors (average 57%, range 0-100%), and they associated these findings with limited success rates from some donors. Regarding implantation, multiple factors can play a role, not just embryo aneuploidy. In this study, we have focused on the percentage of donors' euploid embryos that reached the blastocyst stage as a measure for embryo quality, and uterine factors in the recipients have not been ruled out. We are aware that PGS does not assess the whole chromosomal status and limitations of this approach included the limited number of chromosomes and blastomeres analysed. Newer approaches such as CGH and CGH arrays will allow a more comprehensive analysis of the embryo chromosomal status (Hellani et al., 2008; Fishel et al., 2010; Johnson et al., 2010) . Regardless the technical limitations of our study, our group and other authors have shown that FISH analysis on Day-3 using additional rounds with subtelomeric probes increases the accuracy of the technique and the results are representative of the chromosomal status of the corresponding Day-5 embryo (Colls et al., 2007; Mir et al., 2010) .
In conclusion, despite the limited number of donors included in our study, we suggest that, in high responders, ovarian stimulation protocols affect embryo quality following different patterns and therefore they should be individualized. We should find the 'minimal effective dose' for an optimal IVF outcome in each patient and donor. While a universal protocol will always be more cost-effective, this may not always be the best option to offer.
